Clinical Trial Update: Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial comparing oral topotecan to docetaxel for second-line non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Topotecan (topotecan)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED